Nicholas Short MD (@nicholasshortmd) 's Twitter Profile
Nicholas Short MD

@nicholasshortmd

Associate Professor, Department of Leukemia, MD Anderson Cancer Center - Research interest: phase I/II clinical trials in AML and ALL, developing new MRD assays

ID: 826584913214316546

linkhttps://faculty.mdanderson.org/profiles/nicholas_short.html calendar_today01-02-2017 00:16:15

346 Tweet

1,1K Followers

172 Following

Nicholas Short MD (@nicholasshortmd) 's Twitter Profile Photo

Our paper on aza + ven +gilteritinib for FLT3mut #AML now online at Journal of Clinical Oncology In frontline FLT3mut AML, CR 90% (vs. 30-50% with aza+ven) and 18mo OS 72% (vs. 2yr OS 20-40% with aza+ven) Could be delivered safely with appropriate dose modifications. ascopubs.org/doi/10.1200/JC…

Veera Rajagopal  (@doctorveera) 's Twitter Profile Photo

Someone used DALL-E to create gobbledygook scientific figures and submitted them to Frontiers Journal. And guess what? The editor published it. LOL frontiersin.org/articles/10.33…

Someone used DALL-E to create gobbledygook scientific figures and submitted them to Frontiers Journal. And guess what? The editor published it. LOL
frontiersin.org/articles/10.33…
FDA Oncology (@fdaoncology) 's Twitter Profile Photo

FDA granted accelerated approval to ponatinib with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. fda.gov/drugs/resource… #OCENewsBurst

Anand Patel (@anand_88_patel) 's Twitter Profile Photo

A very nice paper in Blood Journal elucidating the mechanisms of resistance to inotuzumab in B-ALL that go beyond loss of CD22 ashpublications.org/blood/article/…

A very nice paper in <a href="/BloodJournal/">Blood Journal</a> elucidating the mechanisms of resistance to inotuzumab in B-ALL that go beyond loss of CD22

ashpublications.org/blood/article/…
Hagop Kantarjian,MD (@drhkantarjian) 's Twitter Profile Photo

Many pts with Ph+ #ALL can be salvaged with INO, blina or CAR T-cells after ponatinib failure. Long-term remissions possible in some pts without alloSCT Nicholas Short MD MD Anderson Cancer Center #Leukemia pubmed.ncbi.nlm.nih.gov/38607091/ AmericanJournalofHematology #leusm

Nicholas Short MD (@nicholasshortmd) 's Twitter Profile Photo

Our new review on inotuzumab ozogamicin is now online. We cover the clinical development of INO, pivotal studies, and the novel uses of INO in B-ALL, including combination therapies and use in the frontline setting.

Hagop Kantarjian,MD (@drhkantarjian) 's Twitter Profile Photo

NGS MRD (clonoSEQ) is the most sensitive and specific MRD assay in Ph+ #ALL. Therapeutic decision-making should be based on NGS rather than PCR for BCR::ABL1 Nicholas Short MD of MD Anderson Cancer Center #Leukemia doi.org/10.1080/174740… #leusm

Nicholas Short MD (@nicholasshortmd) 's Twitter Profile Photo

Happy to see our trial of DAC, venetoclax and ponatinib for advanced phase CML published in The Lancet Haematology. Response rate was 80%, allowing for bridge to alloSCT. Still a lot more work to be done in this rare disease. We have new TKI combo studies now open and enrolling.

Hagop Kantarjian,MD (@drhkantarjian) 's Twitter Profile Photo

MRD is highly prognostic in #AML and can inform SCT decisions or enrollment into MRD-directed clinical trials. MRD endpoints may also allow for accelerated drug approval in AML. New review by Nicholas Short MD and Richard Dillon in AmericanJournalofHematology doi.org/10.1002/ajh.27… #leusm

MRD is highly prognostic in #AML and can inform SCT decisions or enrollment into MRD-directed clinical trials. MRD endpoints may also allow for accelerated drug approval in AML. New review by <a href="/NicholasShortMD/">Nicholas Short MD</a> and Richard Dillon in <a href="/AjHematology/">AmericanJournalofHematology</a> 
doi.org/10.1002/ajh.27…
#leusm
ALL Hub (@all_hub_) 's Twitter Profile Photo

CONGRESS #ASH24 | PRESENTATION Roberta Santos Azevedo, MD Anderson Cancer Center discussed older age and TP53 mutations as predictors of myeloid neoplasm. Incidence of t-MN was highest in pts older than 60, and also higher with treatment intensity and TP53 mutation. t-MN risk was highest

CONGRESS #ASH24 | PRESENTATION
Roberta Santos Azevedo, <a href="/MDAndersonNews/">MD Anderson Cancer Center</a>  discussed older age and TP53 mutations as predictors of myeloid neoplasm. Incidence of t-MN was highest in pts older than 60, and also higher with treatment intensity and TP53 mutation. t-MN risk was highest
ALL Hub (@all_hub_) 's Twitter Profile Photo

CONGRESS #ASH24 | PRESENTATION Walid Macaron, MD MSc, MD Anderson Cancer Center and BCMHouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1.

CONGRESS #ASH24 | PRESENTATION
<a href="/WNMacaron/">Walid Macaron, MD MSc</a>, <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> and <a href="/bcmhouston/">BCMHouston</a> discussed achievement of MRD negativity and  positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1.
AML Hub (@aml_hub) 's Twitter Profile Photo

CONGRESS | #ASH24 | PRESENTATION Nicholas Short MD MD Anderson Cancer Center shares long-term findings from a study of patients with ND FLT3m AML treated with HMA+Ven+FLT3i triplet (N = 73). ▪️Efficacy overall was comparable to that seen with doublet therapy, and at median follow-up of 26

CONGRESS | #ASH24 | PRESENTATION
<a href="/NicholasShortMD/">Nicholas Short MD</a> <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> shares long-term findings from a study of patients with ND FLT3m AML treated with HMA+Ven+FLT3i triplet (N = 73).
▪️Efficacy overall was comparable to that seen with doublet therapy, and at median follow-up of 26
Hagop Kantarjian,MD (@drhkantarjian) 's Twitter Profile Photo

Early attainment of undetectable MRD by MFC is independently associated w/ improved RFS in newly diagnosed #AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT. MD Anderson Cancer Center #Leukemia ASH ashpublications.org/bloodadvances/…

Early attainment of undetectable MRD by MFC is independently associated w/ improved RFS in newly diagnosed #AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT. 
<a href="/MDAndersonNews/">MD Anderson Cancer Center</a> #Leukemia 
<a href="/ASH_hematology/">ASH</a> 
ashpublications.org/bloodadvances/…
ALL Hub (@all_hub_) 's Twitter Profile Photo

Recommendations from a panel of US experts published in Blood Advances highlight the optimal use of MRD as a prognostic and therapeutic tool in adult ALL More news: loom.ly/EvtL7yw #ALLsm #leusm #MedNews #MedEd

Recommendations from a panel of US experts published in <a href="/BloodAdvances/">Blood Advances</a> highlight the optimal use of MRD as a prognostic and therapeutic tool in adult ALL

More news: loom.ly/EvtL7yw

#ALLsm #leusm #MedNews #MedEd
Hagop Kantarjian,MD (@drhkantarjian) 's Twitter Profile Photo

Expert recommendations on using MRD in #ALL now out in Blood Advances. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT MD Anderson Cancer Center #Leukemia doi.org/10.1182/blooda… #leusm

Expert recommendations on using MRD in #ALL now out in <a href="/BloodAdvances/">Blood Advances</a>. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT
<a href="/MDAndersonNews/">MD Anderson Cancer Center</a> #Leukemia 
doi.org/10.1182/blooda…
#leusm
Blood Advances (@bloodadvances) 's Twitter Profile Photo

Measurable residual disease is a powerful predictor of clinical outcomes in acute lymphoblastic leukemia. ow.ly/Y2iM50VonWG #MRD #ALL #lymphoidneoplasia

Hagop Kantarjian,MD (@drhkantarjian) 's Twitter Profile Photo

WBC >70K (but not IKZF1plus) increases risk of relapse with blina+ponatinib in Ph+ ALL, particularly extramedullary/CNS. Pts with high WBC should be considered for systemic MTX/Ara-C and/or CAR T-cell consolidation jhoonline.biomedcentral.com/articles/10.11… #leusm #ALL

WBC &gt;70K (but not IKZF1plus) increases risk of relapse with blina+ponatinib in Ph+ ALL, particularly extramedullary/CNS. Pts with high WBC should be considered for systemic MTX/Ara-C and/or CAR T-cell consolidation
jhoonline.biomedcentral.com/articles/10.11…
#leusm #ALL